Application of thin layer chromatography in the analysis of efavirenz

Authors

  • Oksana I. Slabiak Ivano-Frankivsk National Medical University, Ukraine
  • Iryna M. Ivanchuk Ivano-Frankivsk National Medical University, Ukraine
  • Lina Yu. Klimenko National University of Pharmacy, Ukraine https://orcid.org/0000-0002-4857-5706
  • Olena Ye. Mykytenko National University of Pharmacy, Ukraine
  • Olga V. Antonenko National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/ophcj.20.197511

Keywords:

efavirenz, thin layer chromatography, color tests

Abstract

Aim. To carry out the integrated study of visualization conditions of efavirenz on TLC-plates with aplication of standard and particular colored reagents, and the chromatographic behavior of efavirenz using standard mobile phases.

Results and discussion. It has been shown that such widely used color reagents as UV-light, Erdmann reagent, Froehde reagent, Liebermann reagent, sulfuric acid, Marquis reagent, Mandelin reagent, acidified iodoplatinate solution, iodine vapor can be used for efavirenz detection on chromatographic plates. Efavirenz gives the positive detection results with reagents used in the TLC-screening of extracts from the biological material for substances of basic, acid and neutral nature. The chromatographic mobility of efavirenz has been studied in 17 solvents systems; the systems are used as standard mobile phases according to the recommendations of the International Association of Forensic Toxicologists for TLC-screening of organic compounds of acid, neutral and basic nature, and as well as in the general TLC-screening of organic substances in the Ukrainian forensic toxicological laboratories.

Experimental part. The chromatographic plates Sorbfil® PTLC-IIH-UV and Merck® TLC Silica gel 60G were used as thin layers.

Conclusions. The behavior of efavirenz when developing on TLC-plates with two types of a substrate (plastic and glass) and with/without a luminophor with commonly used colored reagents has been studied. The Rf values of efavirenz under chromatographing conditions in the standard solvent systems used for TLC-screening of organic compounds of acid, neutral and basic nature have been set.

 

Received: 17.12.2019
Revised: 12.01.2020
Accepted: 27.02.2020

Supporting Agencies

  • The budget themes of the Ministry of Public Health of Ukraine No. 0113U004136
  • No. 011411000958

Downloads

Download data is not yet available.

References

  1. Usach, I.; Melis, V.; Peris, J.-E. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. Journal of the International AIDS Society 2013, 16 (1), 18567. https://doi.org/10.7448/ias.16.1.18567.
  3. Waters, L.; John, L.; Nelson, M. Non-nucleoside reverse transcriptase inhibitors: a review. International Journal of Clinical Practice 2007, 61 (1), 105–118. https://doi.org/10.1111/j.1742-1241.2006.01146.x.
  5. De Clercq, E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Research 1998, 38 (3), 153–179. https://doi.org/10.1016/S0166-3542(98)00025-4.
  7. Rakhmanina, N. Y.; van den Anker, J. N. Efavirenz in the therapy of HIV infection. Expert Opinion on Drug Metabolism & Toxicology 2010, 6 (1), 95–103. https://doi.org/10.1517/17425250903483207.
  9. Bastos, M. M.; Costa, C. C. P.; Bezerra, T. C.; da Silva, F. d. C.; Boechat, N. Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry. Eur. J. Med. Chem. 2016, 108, 455–465. https://doi.org/10.1016/j.ejmech.2015.11.025.
  11. Best, B. M.; Goicoechea, M. Efavirenz – Still First-line King? Expert Opinion on Drug Metabolism & Toxicology 2008, 4 (7), 965–972. https://doi.org/10.1517/17425255.4.7.965.
  13. Andany, N.; Gold, W. L. Single-tablet antiretroviral treatment (once daily). Canadian Medical Association Journal 2016, 188 (13), 971. https://doi.org/10.1503/cmaj.151412.
  15. Kenedi, C. A.; Goforth, H. W. A Systematic Review of the Psychiatric Side-Effects of Efavirenz. AIDS and Behavior 2011, 15 (8), 1803–1818. https://doi.org/10.1007/s10461-011-9939-5.
  17. Decloedt, E. H.; Maartens, G. Neuronal toxicity of efavirenz: a systematic review. Expert Opinion on Drug Safety 2013, 12 (6), 841–846. https://doi.org/10.1517/14740338.2013.823396.
  19. Abers, M. S.; Shandera, W. X.; Kass, J. S. Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs. CNS Drugs 2014, 28 (2), 131–145. https://doi.org/10.1007/s40263-013-0132-4.
  21. Mutwa, P. R.; Fillekes, Q.; Malgaz, M.; Tuyishimire, D.; Kraats, R. v. d.; Boer, K. R.; Burger, D. M.; van Schaik, R. H. N.; Muganga, N.; Geelen, S. P. M. Mid-Dosing Interval Efavirenz Plasma Concentrations in HIV-1–Infected Children in Rwanda: Treatment Efficacy, Tolerability, Adherence, and the Influence of CYP2B6 Polymorphisms. JAIDS Journal of Acquired Immune Deficiency Syndromes 2012, 60 (4), 400–404. https://doi.org/10.1097/QAI.0b013e3182569f57.
  23. Fillekes, Q.; Natukunda, E.; Balungi, J.; Kendall, L.; Bwakura-Dangarembizi, M.; Keishanyu, R.; Ferrier, A.; Lutakome, J.; Gibb, D. M.; Burger, D. M.; Walker, A. S. Pediatric Underdosing of Efavirenz: A Pharmacokinetic Study in Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes 2011, 58 (4), 392–398. https://doi.org/10.1097/QAI.0b013e318235e560.
  25. Mollan, K. R.; Smurzynski, M.; Eron, J. J.; Daar, E. S.; Campbell, T. B.; Sax, P. E.; Gulick, R. M.; Na, L.; O’Keefe, L.; Robertson, K. R.; Tierney, C. Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide: An Analysis of Trial Data. Annals of Internal Medicine 2014, 161 (1), 1–10. https://doi.org/10.7326/m14-0293.
  27. Moffat A.C.; Osselton M.D.; Widdop B. Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material. 4 ed.; Pharmaceutical Press: London, 2011.
  29. Jickells, S.; Negrusz, A., Clarke’s Analytical Forensic Toxicology. Pharmaceutical Press: London, 2008.

Downloads

Published

2020-03-05

How to Cite

(1)
Slabiak, O. I.; Ivanchuk, I. M.; Klimenko, L. Y.; Mykytenko, O. Y.; Antonenko, O. V. Application of Thin Layer Chromatography in the Analysis of Efavirenz. J. Org. Pharm. Chem. 2020, 18, 58-62.

Issue

Vol. 18 No. 1(69) (2020)

Section

Original Researches

License

Copyright (c) 2020 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:

1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.

3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).